The new Swiss CDMO offering phase-adjusted CMC expertise at an attractive cost
ENABLE BIOTECH IS THE RIGHT PARTNER
We address specific challenges of manufacturing advanced therapies.
Learn more about how ENABLE BioTech can become YOUR next generation CDMO.
-
CMC EXPERTISE
Team with specific expertise and capabilities in the field of CGT manufacturing, ensuring a smooth transition of manufacturing processes -
FLEXIBILITY
Transparent collaboration on developing manufacturing and QA process, providing flexibility for future in-house production -
SPEED
Available capacity in SwissMedic accredited GMP facility R&D and manufacturing suites, avoiding delays to First in Human -
AFFORDABILITY
Attractive costs for affordable therapies through use of existing SwissMedic accredited GMP facility
Service Offerings for Cell & Gene Therapy
Production of Cell Therapies, Gene-Modified Cell Therapies, and Exosome Therapies
Utilizing various cell types including PBMC (T Cells, NK cells, Invariant NK Cells) iPSC, MSC, HLSC, and more
Gene editing using viral vectors (AAV, LVV) or electroporation
Preparation of CMC sections in regulatory submissions, anticipating increasing clinical development requirements
Value Proposition
- Focus on client needs & Tailored Services
- Access to wealth of experience in the ENABLE Biotech network (QC, RA, QP, QA (beyond normal routine), CMC, Engineering
- Novel Operating Model permitting efficient work execution and attractive pricing in sync with early-stage clinical client needs
Focusing only on the needs of clinical stage companies pursuing a phase-adapted approach towards compliance, Enable Biotech has established an innovative setup for development and clinical manufacturing capacity, capabilities, and resources enabling a very attractive pricing structure.
With its network and team of highly qualified experts in the field that support special activities (RA, QP, QA (beyond normal routine), CMC, Engineering) ad hoc on demand to reduce basic operation costs while keeping access to their valuable knowledge, Enable Biotech is best positioned to ensure project realization that incorporates closely the project sponsor while providing guidance and making the wealth of existing experience available / accessible.
Infrastructure
Key Equipment
- CliniMACS PLUS® & Prodigy® Automated Cell Processing Closed Systems
- Lovo® Automated Cell Processing System
- G-Rex® (Gas Permeable Rapid Expansion) Platform
- ExoView™ R100 for Complete Extracellular Vesicle Characterization
- CTS™ DynaBeads System for Ex Vivo Isolation, Activation, & Expansion of T-Cells
- Vi-Cell BLU Cell Viability Analyzer
- NTA Exosome Counter
- The Exoid TRPS System for Nanoparticle Characterization
About Us
Alain Pralong
Chief Executive Officer
PhD in Molecular & Cell Biology
Yves Maag
Chief Operating Officer
Renaud Jacquemart
Chief Commercial Officer
MBA, PhD in Chemical Engineering
News
ENABLE Biotech Next-Generation ATMP CDMO Capacity Update
ENABLE Biotech’s focus is on providing start-up and spin-out companies in the advanced therapy space with a partner to support their unique challenges when it comes to preparing for early-stage clinical development. The team brings specific expertise and capabilities in process development and manufacturing ensuring a smooth transition into early-stage clinical testing.
Advanced Therapy Manufacturing for Start-Ups: The Need for a Next Generation CDMO
The cell and gene therapy sector is booming, with over 90 new trials in 2023 and nearly 4,000 treatments in progress. Small biotechs, often university spin-offs, are driving innovation but lack the resources for in-house manufacturing, leading 75% to partner with CDMOs. Yet, these start-ups have specific early-stage development needs not fully met by current CDMOs, necessitating a new model that offers tailored expertise and flexible pricing to support their unique challenges in this rapidly evolving field.
Contact
Enable Biotech Ltd.
Baarerstrasse 8
6300 Zug
Mail: contact@enablebiotech.ch
Tel: +41 41 244 06 66